Literature DB >> 436357

Single and divided doses of penbutolol.

F O Müller, H K Hundt, P A Bromley, J Torres, O Vanderbeke.   

Abstract

Penbutolol, a nonselective beta-adrenoreceptor antagonist, induced reduction of exercise-induced heartbeats for at least 24 hr after a single 40-mg oral dose, and was equipotent with respect to a 2 X 20-mg regimen over the same period. Ingestion for 7 days did not influence the pharmacodynamics or pharmacokinetics of penbutolol, and there was no cumulation of drug in serum. A relationship was found between the logarithms of measurable serum concentrations of penbutolol and the percentage reduction of total heartbeats. Absorption of oral penbutolol appeared to be reduced when administered in the evening. Since beta-adrenoceptor activity was relatively unchanged between 13 and 24 hr after a single 40-mg dose of penbutolol, there is a possibility that an active metabolite or metabolites may contribute to prolonged duration of action.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436357     DOI: 10.1002/cpt1979255part1528

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Authors:  D Brockmeier; P Hajdù; W Henke; E Mutschler; D Palm; W Rupp; H Spahn; M T Verho; A Wellstein
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Pharmacokinetics of penbutolol and its metabolites in renal insufficiency.

Authors:  N Bernard; G Cuisinaud; N Pozet; P Y Zech; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.

Authors:  A Wellstein; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Pharmacodynamic and pharmacokinetic study of oral and intravenous penbutolol.

Authors:  J A Vedin; C Wilhelmsson; L Maass; L E Peterson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Penbutolol: a preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-07       Impact factor: 9.546

6.  Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.

Authors:  H Spahn; W Kirch; P Hajdu; E Mutschler; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris.

Authors:  B Silke; S P Verma; M Hussain; G I Nelson; R C Okoli; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

8.  Penbutolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements.

Authors:  J F De Plaen; E Vander Elst; C Van Ypersele de Strihou
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

Review 9.  Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.

Authors:  Aikaterini Zisaki; Ljubisa Miskovic; Vassily Hatzimanikatis
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

10.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.